Evaluation of in vitro chemosensitivity using human lung cancer cell lines

Journal of Cellular Biochemistry

Volumn 62, Issue SUPPL. 24, 1996, Pages 160-164

  Kratzke, Robert A ^a   Kramer, Barnett S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemosensitivity; lung cancer; MTT; supraadditive; synergy

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; FORMAZAN; ANTINEOPLASTIC AGENT; COLORING AGENT; MTT FORMAZAN; TETRAZOLIUM;

CANCER CELL; CELL LINE; CHEMOSENSITIVITY; DOSE RESPONSE; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CARCINOGENESIS; METABOLIC REGULATION; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; ANIMAL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; LUNG TUMOR; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; COLORING AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FORMAZANS; HUMANS; LUNG NEOPLASMS; MICE; TETRAZOLIUM SALTS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 33646951899     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.240630511     Document Type: Review

References (31)

1. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD (1985): Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913-2923.
2. Kratzke RA, Shimizu E, Kaye, FJ (1992): Molecular genetics of lung cancer. In Benz C, Yu E (eds): "Tumor Suppressors and Oncogenes in Human Malignancies." Boston: Kluwer Academic Publishers, pp 61-85.
3. Ihde DC (1992): Chemotherapy of lung cancer. N Engl J Med 327:1434-1441.
4. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Liber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, Von Hoff DD (1985): Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45:2145-2153.
5. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990): Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113-1118.
6. Weisenthal LM, Dill PL, Kurnick NB, Lippman ME (1983): Comparison of dye exclusion assays with a clonogenic assay in determination of drug induced cytotoxicity. Cancer Res 43:258-264.
7. Ajani JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C (1987): Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol 5:1912-1921.
8. Yuhas JM, Tarleton AE, Harman JG (1978): In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo. Cancer Res 38:3595-3598.
9. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Gosh BC, Cotelingham JD, Johnson BE, Minna JD, Ihde DC (1990): Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: A prospective trial. J Natl Cancer Inst 82:117-124.
10. Bogden AE, Von Hoff DD (1984): Comparison of the human tumor cloning and subrenal capsule assays. Cancer Res 44:1087-1090.
11. Noso Y, Niimi K, Nishiyama M, Hirabayashi N, Toge T, Niimoto M, Hattori T (1987): Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation. Cancer Res 47:6418-6422.
12. Mossman T (1983): Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
13. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987): Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47:5875-5879.
14. Cole SPC (1986): Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 17:259-263.
15. Campling BG, Pym J, Baker HM, Cole SPC, Lam Y-M (1991): Chemosensitivity testing small cell lung cancer using the MTT assay. Br J Cancer 63.75-83.
16. DeVita VT Jr (1989): Principles of chemotherapy. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): "Cancer: Principles and Practice of Oncology," 3rd edition. Philadelphia: J.B. Lippincott, pp 276-300.
17. Steel GG, Peckham MJ (1979): Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91.
18. Berenbaum MC (1989): What is synergy? Pharmacol Rev 41:93-141.
19. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr (1979): cis-Dichlorodiammineplatinum(II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459-1473.
20. Tsai C-M, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL, Mulshine JL, Kramer BS (1989): Lack of in vitro synergy between etoposide and cis-diammine-dichloroplatinum(II). Cancer Res 49:2390-2397.
21. Tsai C-M, Gazdar AF, Perng R-P, Kramer BS ( ): Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. Int J Cancer 47:401-407.
22. Benz C, Shoenberg M, Choti M, Cadman E (1980): Schedule-dependent cytotoxicity of methotrexate and 5-fluoruracil in human colon and breast tumor cell lines. J Clin Invest 66:1162-1165.
23. Bertino JR, Mini E, Fernandes DJ (1983): Sequential methotrexate and 5-fluorouracil: Mechanisms of synergy. Semin Oncol 10:1983.
24. Tsai C-M, Hsiao S-H, Frey CM, Chang K-T, Perng R-P, Gazdar AF, Kramer BS (1992): The combination cytotoxic effects of cis-Diammine-dichloroplatinum(II) and 5-Fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines.
25. Dreyfuss AI, Clark JR, Wright JE, Norris CM Jr, Busse PM, Lucarini JW, Fallon BG, Casey D, Anderson JW, Klein R, Rosowsky A, Miller D, Frei E (1990): Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Int Med 112:167-172.
26. Vokes EE, Schilsky RL, Weischelbaum RR, Kozloff MF, Panje WR (1990): Induction chemotherapy with cisplatin, fluorouracil, and high dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacologie analysis. J Clin Oncol 8:241-247.
27. Vokes EE, Schilsky RL, Weischelbaum RR, Gusapiri A, Guarnieri CM, Whaling SM, Panje WR (1989): Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer 63:1048-1053.
28. Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weischelbaum RR, Panje WR (1988). Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618-626.
29. Tsai C-M, Gazdar AF, Allegra C, Perng R-P, Kramer BS (1990): Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines. Int J Cancer 46:101-105.
30. Allegra CJ (1991): Biochemical modulation: A therapy that has come of therapeutic age. J Clin Oncol 9:1723-1726.
31. Dearing MP, Englee-Miller MJ, Kramer BS, Chu E, Mulshine JL, Gazdar AF (1990): Enhanced kill of human lung cancer cell lines by 10-Ethyl- 10-deazaaminopterin (10-EDAM) when given with Dipyridamole (DPM). Proc Am Assoc Cancer Res 31:101.